This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Howard, D. N Articles by Cusano, F. Search for Related Content PubMed PubMed Citation Articles by Howard, D. N Articles by Cusano, F. Social Bookmarking                         What's this?

Efficacy vs. effectiveness — docetaxel and prednisone in hormone refractory prostate cancer

Pharmacy department, Tom Baker Cancer Center 1331 - 29 Street N.W. Calgary, Alberta Canada T2N 4N2

Carole Chambers, BSc Pharm MBA

Pharmacy department, Tom Baker Cancer Center 1331 - 29 Street N.W. Calgary, Alberta Canada T2N 4N2, carolech{at}cancerboard.ab.ca

Frances Cusano, BSc Pharm

Pharmacy department, Tom Baker Cancer Center 1331 - 29 Street N.W. Calgary, Alberta Canada T2N 4N2

Objectives. To assess the clinical effectiveness of docetaxel and prednisone in a clinical setting and to compare the results to those seen in the pivotal clinical trial. To assess the impact of various factors on the prognosis of patients treated with docetaxel.

Design. Retrospective chart review. The primary outcome measured was survival. Survival data was analyzed through the Kaplan—Meier methodology. A multivariate analysis of prognostic variables was also conducted.

Setting. Public cancer centers within the Canadian province of Alberta.

Patients. Hormone refractory, metastatic prostate cancer patients initiated on docetaxel chemotherapy between September 2004 and February 2007 within the Alberta Cancer Board.

Main Outcome Measured. The primary outcome measured was median survival.

Results. Among 161 patients eligible for review, median survival was 17.22 months. Chemotherapy received after docetaxel was determined to be a significant favorable prognostic factor for survival ( p<0.0001).

Conclusion. In a clinical setting, docetaxel and prednisone did not perform as well in terms of median survival, as it was shown to in prior clinical trials (17.22 vs. 18.9 months). Further investigation into the impact of docetaxel and prednisone on quality of life in clinical practice, would complement the findings of this study. J Oncol Pharm Practice (2008) 14: 45—49.

Key Words: effectiveness • docetaxel • prostate cancer

Journal of Oncology Pharmacy Practice, Vol. 14, No. 1, 45-49 (2008)
DOI: 10.1177/1078155207085387


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?